参芪扶正注射液配合化疗治疗中晚期大肠癌的临床研究  

Effect of Shenqi Fuzheng Injection Combined with Chemotherapy in Treating Advanced Colorectal Carcinoma

作　　者：梁启廉[1] 潘达超[1] 谢杰荣[1] 蔡良真[1] 李姝君[1] 杨勤[1] 

机构地区：[1]广东医学院附属医院肿瘤中心,广东湛江524001

出　　处：《中国中西医结合杂志》2009年第5期439-441,共3页Chinese Journal of Integrated Traditional and Western Medicine

摘　　要：目的比较参芪扶正注射液联合化疗与单纯化疗治疗中晚期大肠癌的临床疗效及不良反应。方法152例中晚期大肠癌患者采用随机数字表法分为治疗组76例和对照组76例,治疗组采用参芪扶正注射液加FO LFOX化疗方案治疗,对照组采用单纯FO LFOX方案化疗,对两组疗效及不良反应进行评价。结果治疗组和对照组有效率(CR+PR)分别为63.2%(48/76)、46.1%(35/76)(P<0.05),治疗组中位生存期为31周,对照组中位生存期为28周,治疗组治疗后T淋巴细胞亚群中的CD4/CD8比值(1.56±0.21,1.64±0.28)有明显提高(P<0.05),而对照组治疗后比值(1.58±0.22,1.46±0.33)有明显降低(P<0.01),生活质量治疗组高于对照组(P<0.05),恶心呕吐反应及白细胞减少治疗组低于对照组(P<0.05)。结论参芪扶正注射液联合化疗能提高治疗有效率、延长中位生存期、减轻化疗某些不良反应(恶心呕吐、白细胞减少)、降低化疗对大肠癌患者免疫功能的影响、改善生活质量。Objective To compare the therapeutic effect and toxicity of chemotherapy, used alone or in com- bined with Shenqi Fuzheng Injection （SFI）, for the treatment of advanced colorectal carcinoma （ACRC）. Methods One hundred and fifty-two patients with ACRC were equally randomized by digital table, to the treated group, treated by chemotherapy of FOLFOX regimen combined with SFI, and the control group treated by FOLFOX regimen alone. The therapeutic effect and adverse reaction of the treatment in patients were assessed. Results The effective rate （CR ＋ PR） was 63. 2% （48/76） in the treated group and 46. 1% （35/76） in the control group, showing significant difference between the two groups （ P 〈 0. 05）. The median survival time in the two groups was 31 weeks and 28 weeks respectively. CD4/CD8 ratio was significantly increased in the treated group （1.56 ±0. 21, 1.64 ±0. 28, P 〈0. 05）, but significantly decreased in the control group （1.58 ±0. 22,1.46 ±0. 33, P 〈0. 01 ）. Quality of life in the former group was higher than that in the latter group （P 〈0. 05）. Times/case of nausea, vomiting, leukopenia occurring in the control group was more than those in the treated group A （ P 〈0.05）. Conclusion By combining with SFI, some adverse reactions of chemotherapy （such as nausea, vomiting, leukopenia） and its influence on patients＇ immunity could be alleviated in treating ACRC, which might enhance the efficacy of chemotherapy, and improve the quality of life and prolong the median survival time in patients.

关 键 词：大肠癌 参芪扶正注射液 化疗 

分 类 号：R735.34[医药卫生—肿瘤]